{"id":"rubidium-82","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure (minimal, diagnostic dose)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Chest discomfort (stress-induced)"}]},"_chembl":{"chemblId":"CHEMBL1200727","moleculeType":"Small molecule","molecularWeight":"117.37"},"_dailymed":{"setId":"ee95aa18-9f2f-40eb-9b4c-583bea6f36bf","title":"CARDIOGEN-82 (RUBIDIUM CHLORIDE RB-82) INJECTION, SOLUTION [BRACCO DIAGNOSTICS INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rubidium-82 is produced from a strontium-82/rubidium-82 generator and behaves similarly to potassium, being taken up by viable myocardium via Na+/K+-ATPase pumps. The positron emissions are detected by PET cameras to create real-time images of myocardial perfusion at rest and during stress, enabling assessment of coronary artery disease and myocardial viability.","oneSentence":"Rubidium-82 is a positron-emitting radioisotope that accumulates in myocardial tissue proportional to blood flow, allowing visualization of cardiac perfusion via PET imaging.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:57.866Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myocardial perfusion imaging for detection of coronary artery disease"},{"name":"Assessment of myocardial viability in patients with coronary artery disease"}]},"trialDetails":[{"nctId":"NCT06965621","phase":"PHASE2","title":"18F-mFBG Imaging for Myocardial Sympathetic Innervation","status":"NOT_YET_RECRUITING","sponsor":"Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)","startDate":"2026-04-28","conditions":"Heart Failure, Ischemic Cardiomyopathy, ICD Patients","enrollment":20},{"nctId":"NCT07346404","phase":"PHASE2","title":"Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-01","conditions":"Renal Cell Carcinoma","enrollment":50},{"nctId":"NCT07099404","phase":"","title":"Parathyroid Adenoma Detection With Rubidium-82 Imaging","status":"NOT_YET_RECRUITING","sponsor":"Matthieu Pelletier-Galarneau, MD MSc","startDate":"2025-11","conditions":"Parathyroid Adenomas, Hyperparathyroidism, Primary","enrollment":20},{"nctId":"NCT07120776","phase":"NA","title":"Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Manchester","startDate":"2025-09","conditions":"Hypertrophic Obstructive Cardiomyopathy \\(HOCM\\), Left Ventricular Outflow Tract Obstruction, Myocardial Ischaemia","enrollment":75},{"nctId":"NCT02280941","phase":"NA","title":"Cadmium-zinc-telluride (CZT) Imaging of Myocardial Blood Flow (MBF) (SPECT MBF)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2014-10-30","conditions":"Coronary Heart Disease","enrollment":66},{"nctId":"NCT03344159","phase":"PHASE4","title":"Spironolactone Therapy in Chronic Stable Right HF Trial","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2018-04-01","conditions":"Chronic Right-Sided Heart Failure, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Primary, 2","enrollment":15},{"nctId":"NCT03809689","phase":"NA","title":"Study of Cardiac Lesions Angiogenesis by 68Ga-NODAGA-RGD Cardiac PET","status":"TERMINATED","sponsor":"University of Lausanne Hospitals","startDate":"2018-11-01","conditions":"Myocardial Infarction, Acute, Myocardial Reperfusion, Chronic Ischemic Heart Disease","enrollment":24},{"nctId":"NCT05037799","phase":"","title":"Dose Optimization for Rubidium PET Imaging in Patients With Known or Suspected Ischemic Heart Disease","status":"UNKNOWN","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2022-07-01","conditions":"Ischemic Heart Disease","enrollment":48},{"nctId":"NCT05286593","phase":"PHASE4","title":"3D PET Myocardial Blood Flow and Rb82 Infusion Profiles","status":"COMPLETED","sponsor":"Ochsner Health System","startDate":"2021-12-28","conditions":"Normal Healthy Volunteers Without Chronic Medical Conditions, Coronary Artery Disease, Cardiac Risk Factors","enrollment":98},{"nctId":"NCT02043535","phase":"NA","title":"CO2 as a Stress Agent for Perfusion Imaging","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2014-03-12","conditions":"Coronary Artery Disease","enrollment":20},{"nctId":"NCT04475094","phase":"","title":"Impact of Coronary Artery Stenting on Quantitative Myocardial Blood Flow and Health Status","status":"UNKNOWN","sponsor":"Cardiovascular Imaging Technologies","startDate":"2019-12-23","conditions":"Coronary Artery Disease","enrollment":75},{"nctId":"NCT02970851","phase":"","title":"Bosentan in Myocardium Metabolism and Perfusion Measured by 18F-FDG and 82Rb PET/CT on PAH and CTEPH","status":"TERMINATED","sponsor":"University of Lausanne Hospitals","startDate":"2013-04","conditions":"Myocardial Dysfunction, Endothelial Dysfunction","enrollment":2},{"nctId":"NCT01128023","phase":"","title":"Rubidium-82 - An Alternative Radiopharmaceutical for Myocardial Imaging(Rb-ARMI)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2010-04","conditions":"Coronary Artery Disease","enrollment":10000},{"nctId":"NCT01433705","phase":"PHASE1","title":"Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2011-11","conditions":"Heart Disease","enrollment":70},{"nctId":"NCT02117284","phase":"","title":"Rubidium Elution System Performance Testing","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2014-01","conditions":"Coronary Artery Disease","enrollment":15800},{"nctId":"NCT01109992","phase":"PHASE4","title":"Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-02","conditions":"Coronary Artery Disease","enrollment":43},{"nctId":"NCT01919450","phase":"PHASE4","title":"Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation","status":"COMPLETED","sponsor":"Timothy M. Bateman, MD","startDate":"2013-07","conditions":"Myocardial Blood Flow Reserve","enrollment":80},{"nctId":"NCT02003456","phase":"EARLY_PHASE1","title":"Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2013-12","conditions":"Ischemic Heart Disease, Myocardial Infarction","enrollment":30},{"nctId":"NCT01179230","phase":"","title":"Rubidium-82 Position Emission Computed Tomography (PET) Versus Gated, Rest / Stress Technetium 99-m SPECT","status":"COMPLETED","sponsor":"Hartford Hospital","startDate":"2005-01","conditions":"Coronary Artery Disease, Myocardial Ischemia, Heart Disease","enrollment":136},{"nctId":"NCT01379677","phase":"PHASE3","title":"Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2011-02","conditions":"Coronary Artery Disease","enrollment":135},{"nctId":"NCT01254591","phase":"NA","title":"Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer","status":"UNKNOWN","sponsor":"University College London (UCL) Cancer Institute","startDate":"2006-11","conditions":"Breast Cancer, Colorectal Cancer, Esophageal Cancer","enrollment":500},{"nctId":"NCT01424774","phase":"","title":"Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2011-09","conditions":"Radiation Exposure","enrollment":155},{"nctId":"NCT01430975","phase":"","title":"Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2011-09","conditions":"Radiation Exposure","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":400,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Myocardial Perfusion PET","CardioGen-82"],"phase":"marketed","status":"active","brandName":"Rubidium-82","genericName":"Rubidium-82","companyName":"Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)","companyId":"innervate-radiopharmaceuticals-llc-formerly-illumina-radiopharmaceuticals-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rubidium-82 is a positron-emitting radioisotope that accumulates in myocardial tissue proportional to blood flow, allowing visualization of cardiac perfusion via PET imaging. Used for Myocardial perfusion imaging for detection of coronary artery disease, Assessment of myocardial viability in patients with coronary artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}